A second study demonstrated that nanoparticles encapsulating a STING agonist and coated with dual anti-CD47/anti–PD-L1 antibodies mediated robust antitumor efficacy in murine gliomas (56). The gene discussed is CD47; the disease is central nervous system cancer.